CD137 Agonists Market: Competitive Landscape, Pipeline, and Market Analysis 2023

Purchase Option

$ 3000
$ 6601
$ 8900

CD137 (Cluster Differentiation 137) also known as immune checkpoint, is a type 1 transmembrane protein, expressed on the cell surface after T cell activation. CD137 acts as a co-stimulatory molecule functioning to stimulate T cell proliferation, dendritic cell maturation, and promotion of B cell antibody secretion. CD137 agonists exert their effect by stimulating cytotoxic T cell response against tumor cells resulting in tumor clearance, which is achieved by promoting the proliferation and survival of activated CD8+ T cells and upregulating their activity and effector functioning allowing for increased levels of cytokine production, which results in increased formation of memory T cells crucial for creating a long-term tumor response. CD137 agonists are currently in clinical trial phases for conditions such as solid tumors, colorectal cancer, non-hodgin’s lymphoma, malignant melanoma, anal cancer, cervical cancer, head and neck cancer, acute myeloid leukaemia, and others. BMS, Ono Pharma, Pfizer, Biokin Pharma, BeiGene, Crescendo Biologics, Roche are some of the major players in the CD137 agonists market.

Key Market Developments:

  • In Apr 2023, Harbour BioMed’s HBM-7008, a CD137 agonist was licensed to Cullinan Oncology in the USA, Australia, and Europe.

Approved Drug Molecules and Brand Names for CD137 Agonists:

  • Urelumab (BMS-663513)
  • Utomilumab (PF-05082566)
  • ADG106
  • Emfizatamab (GNC-038)
  • LVGN6051
  • GEN1042
  • HLX35
  • INBRX-105
  • Acasunlimab (GEN1046)
  • Cinrebafusp alfa (PRS-343)
  • ABP-300
  • ATG-101
  • BGB-B167
  • CB307
  • DSP-107
  • EU101
  • PE0116
  • PRS-344
  • QLF31907
  • RG7827
  • YH004
  • Sytalizumab (TWP-101)
  • ABL105
  • ABL503
  • ADG206
  • AGEN2373
  • AP203
  • ATOR-1017
  • BI 765179
  • BT7480
  • CTX-471
  • EU204
  • EU210
  • FS120
  • FS222
  • GNC-039

Drugs under the Pipeline for CD137 Agonists:

  • Ganetespib (ADX-1612)
  • GSK2636771
  • Paxalisib
  • MEN1611
  • Gedatolisib
  • TL117
  • IBI376
  • IPI-549 (Enganelisib)
  • Ribociclib
  • HMPL-689

Clinical Activity and Developments of CD137 Agonists:

Currently, there are more than 50 drug products in the CD137 Agonists, and all of them are in the clinical development phases.

  • In Sep 2022, Pieris Pharmaceuticals completed enrolment of patients in phase-II trial in gastric cancer as second-line therapy in South Korea and the USA.
  • In Apr 2023, Sichuan Baili Pharmaceutical initiated a phase-Ib/II trial for T-cell lymphoma ad non-hodgkin’s lymphoma in China for Emfizatamab.

Molecular Name

Number of Studies

Urelumab (BMS-663513)

19

Utomilumab (PF-05082566)

17

ADG106

8

Emfizatamab (GNC-038)

6

LVGN6051

5

GEN1042

3

HLX35

3

INBRX-105

3

Acasunlimab (GEN1046)

3

Cinrebafusp alfa (PRS-343)

3

ABP-300

2

ATG-101

2

BGB-B167

2

CB307

2

DSP-107

2

EU101

2

PE0116

2

PRS-344

2

QLF31907

2

RG7827

2

YH004

2

Sytalizumab (TWP-101)

2

ABL105

1

ABL503

1

ADG206

1

AGEN2373

1

AP203

1

ATOR-1017

1

BI 765179

1

BT7480

1

CTX-471

1

EU204

1

EU210

1

FS120

1

FS222

1

GNC-039

1

Target Indication Analysis of CD137 Agonists

CD137 agonists are currently in preclinical trials for colorectal cancer, in phase-I for solid tumors, non-hodgkin’s lymphoma, malignant melanoma, anal cancer, cervical cancer, head and neck cancer, glioma, follicular lymphoma, ovarian cancer, leukaemia, and others, in phase-I/II for acute myeloid leukaemia, diffuse large B cell lymphoma, squamous cell cancer, HER2 negative breast cancer, non-small cell lung cancer, and others, in phase-II for breast cancer, oropharyngeal cancer, gastric cancer, and others.

Frequently Asked Questions

Urelumab (BMS-663513), Utomilumab (PF-05082566), Emfizatamab (GNC-038), Acasunlimab (GEN1046), Cinrebafusp alfa (PRS-343), and Sytalizumab (TWP-101) are some of the drugs in the pipeline for CD137 agonists.

BMS, Ono Pharma, Pfizer, Biokin Pharma, BeiGene, Crescendo Biologics, Roche are some of the major players in the CD137 agonists market.

Major indications for CD137 agonists are acute myeloid leukaemia, diffuse large B cell lymphoma, squamous cell cancer, HER2 negative breast cancer, non-small cell lung cancer, breast cancer, oropharyngeal cancer, and gastric cancer.

There are more than 50 molecules in the clinical development phases for CD137 agonists.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
  • BMS
  • Ono Pharma
  • Pfizer
  • Biokin Pharma
  • BeiGene
  • Crescendo Biologics
  • Roche
  • TheraWisdom Biopharma
  • Gilead Sciences
  • AP Biosciences
  • Alligator Biosciences
  • Boehringer Ingelheim
  • Bicycle Therapeutics
  • Sino Biopharma

Adjacent Markets